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Abstract
Purpose The use of estimated glomerular filtration rate
(eGFR) in daily clinical practice.
Methods eGFR is a key component in drug therapy manage-
ment (DTM) in patients with renal impairment. eGFR is rou-
tinely reported by laboratories whenever a serum creatinine
testing is ordered. In this paper, we will discuss how to use
eGFR knowing the limitations of serum creatinine-based
formulas.
Results Before starting a renally excreted drug, an equally
effective drug which can be used more safely in patients with
renal impairment should be considered. If a renally excreted
drug is needed, the reliability of the eGFR should be assessed
and when needed, a 24-h urine creatinine clearance collection
should be performed. After achieving the best approximation
of the true GFR, we suggest a gradual drug dose adaptation
according to the renal function. A different approach for drugs
with a narrow therapeutic window (NTW) is recommended
compared to drugs with a broad therapeutic window. For prac-
tical purposes, a therapeutic window of 5 or less was defined
as a NTWand a list of NTW drugs is presented. Considerations
about the drug dose may be different at the start of the therapy
or during the therapy and depending on the indication.
Monitoring effectiveness and adverse drug reactions are impor-
tant, especially for NTW drugs. Dose adjustment should be
based on an ongoing assessment of clinical status and risk
versus the benefit of the used regimen.
Conclusion When determining the most appropriate dosing
regimen serum creatinine-based formulas should never be
used naively but always in combination with clinical and phar-
macological assessment of the individual patient.
Keywords Glomerular filtration rate . Renal function . Drug
dose . Therapeutic window . Adverse drug reaction
Introduction
Ten to 32 % (in elderly patients) of adverse drug reactions
(ADRs) that necessitated hospital admission were related to
impaired renal function [1, 2]. Drug therapy adjustment ac-
cording to renal function is therefore of major importance to
improve drug therapy management (DTM).
The glomerular filtration rate (GFR) is widely accepted as
the preferred index of the kidney function [3]. Since the intro-
duction of the Modification of Diet in Renal Disease (MDRD)
formula [4], laboratories routinely report the estimated GFR
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(eGFR) when serum creatinine testing is ordered [5–7]. More
recently, the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formulas for eGFR were developed
[8]. All formulas have in common are that they are based on
serum creatinine levels. However, there are several factors
which may influence serum creatinine levels and therefore,
eGFR without affecting true GFR itself. These factors vary
from analytical variations to patient characteristics, such as
muscle mass and liver function [9–12]. Inaccuracy in eGFR
values might lead either to overestimation of kidney function,
leading to administration of inappropriately large doses and
therefore possible toxicity, or, conversely, underestimation of
kidney function, leading to subtherapeutic dosing and there-
fore treatment failure and prolonged illness [13]. The theoret-
ical effect of the possible overestimation and underestimation
of true GFR is illustrated in Online Resource 1. The inaccu-
racy of the eGFR may lead to a different renal function group
than the renal function group to which the patient actually
belongs to according the mGFR.
Despite the limitations, serum creatinine-based formulas
are routinely used in daily clinical practice [14–17]. In this
paper, we will discuss approaches on how to use serum
creatinine-based formulas in daily clinical practice in a well-
informed way.
Risk-benefit ratio
The first question after defining the patient’s health problem
is: “What is the therapeutic objective?” [18]. In general, the
goal of DTM is to optimize the risk-benefit ratio and to attain
an optimal therapeutic outcome [19]. In the situation of pa-
tients with renal impairment, this goal is not any different. In a
lifesaving situation, for example, a treatment with antibiotics
in a high dose in case of sepsis, the risk of developing ADRs is
less important than the risk to give an insufficient drug dose
which may lead to untimely death. In less urgent situations,
such as treating hypertension, a more conservative drug dose
can be given at the start of the therapy. And can be gradually
increased with monitoring effect (blood pressure) and/or
ADRs. In other words: “start low, go slow.”
For patients with renal impairment the risk-benefit ratio
should be taken into account when answering the following
questions:
1. Can I use the eGFR reported by laboratories in DTM?
2. Is there an equally effective drug which can be used more
safely in patients with renal impairment?
3. What are the chances and risks of reaching drug levels
outside the therapeutic window?
(a) Considerations at start of pharmacotherapy
(b) Considerations during pharmacotherapy
4. Is it possible to monitor effectiveness and/or ADRs in
order to timely intervene and/or to prevent serious
situations?
How to apply eGFR in daily clinical practice
When there are no reasons to suspect that the true GFR is
substantially different from the eGFR, it can be used without
restrictions.
In cases of rapidly changing GFR, the serum creatinine
levels will not reflect the actual GFR until steady-state has
been reached [19, 20]. In such situations, assessment of im-
paired renal function must rely on multiple measurements
[21]. The modified Jelliffe formula may be useful in measur-
ing an unstable renal function because it uses pairs of serum
creatinine samples instead of only one sample [22, 23].
However, further comparative studies of GFR estimation in
patients with unstable renal function are still needed. In addi-
tion, it is unclear how to adjust drug doses in unstable
situations.
In specific patients and/or clinical situations (e.g.,
malnourishment, relatively low or high muscle mass, acute
critical illness) where estimating equations are known to be
inaccurate or clinical decision-making requires a greater accu-
racy than expected from eGFR, the GFR should be measured
[19, 24]. Measurement of GFR is ideally performed with gold
standards such as 51chromium ethylenediaminetetraacetic acid
(51Cr-EDTA), technetium-labeled diethylene-triamine-
pentacetate (99mTc-DTPA), iohexol, inulin, and iothalamate
[10, 25]. However, these markers are impractical for routine
clinical use due to limited access to necessary diagnostic fa-
cilities and high cost [26]. Twenty-four-hour urine creatinine
clearance collection is easier to perform, especially in the hos-
pital care setting, and might be helpful. It can be used to find
out if the estimation is inadequate due to abnormal muscle
mass. If the creatinine clearance points in the same direction
as the eGFR, the eGFR can be used for decision-making. In
the ambulatory care setting, this method might be more incon-
venient for the patient and prone to failure of collection of the
entire specimen [26, 27].
Recently, the European Medicines Agency advised to use
the absolute eGFR in drug dosing [28]. However, the reason
that the normalized eGFR is used worldwide is the lack of the
availability of weight as a parameter. The difference between
normalized (ml/min/1.73 m2) and absolute (ml/min) eGFR
values should only be taken into account when someone is
substantially larger or smaller than an average person, but with
a normal figure (with a body surface area (BSA) of 1.73 m2).
The best descriptor of body size in obese patients is still un-
clear [29]. The GFR increases with body size but does not
increase in proportion to the total body weight [6].
Therefore, adjustment of eGFR to absolute GFR using BSA
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calculated with actual body weight causes errors in obese pa-
tients [6, 30]. A recent study suggests the use of ideal body
weight as the body size descriptor for GFR indexation [31],
although others suggest the lean body weight [30, 32].
In summary, the reported eGFR by laboratories may
not reflect the true GFR of the individual patient. To make
it even more complicated, most drug dose recommenda-
tions in patients with renal impairment are based on the
Cockcroft and Gault (CG) formula, representing renal
clearance of creatinine instead of eGFR. This might lead
to clinically relevant problems, for example, when using
the new thrombin inhibitors, such as dabigatran and
rivaroxaban [33–35]. The use of the MDRD-4 formula
instead of the CG formula (used in clinical trials) would
result in higher doses or incorrect judgment if patients are
eligible for treatment [34, 35]. Dabigatran would be rec-
ommended in a full dose for 33 % of all participants when
using the CG formula compared to 67 % when using the
MDRD-4 formula [34]. Safety has not been established
using the MDRD equation. This is a concern since the
risk of major bleeding or the development of thrombosis
would be increased in patients with renal impairment [35].
All in all, there are many uncertainties when using eGFR in
DTM. In the following paragraphs, we will outline possible
considerations when prescribing drugs in patients with renal
impairment and how to cope with the knowledge and uncer-
tainties we know today.
Choice of drug
As in every step of prescribing drugs, the benefits should
outweigh the risk. In patients with renal impairment, alterna-
tives for drugs that are renally excreted, should be considered.
There are often alternatives available. For some drug classes,
there are several alternatives, for example, in the drug class of
statins. Only rosuvastatin is contraindicated in severe renal
impairment, whereas the other statins are not [36]. If a 65-
year-old woman is diagnosed with diabetes mellitus type 2
with an eGFR of 35 ml/min/1.73 m2 is metformin still the
drug of choice? Metformin according to the guidelines may
be started in a low dose of 500 mg two times daily. The risk of
metformin-associated lactic acidosis increases when renal
function drops below 30 ml/min/1.73 m2 [37]. This risk is
probably already increased in the 65-year-old woman, be-
cause the eGFR is near the cutoff value of 30 ml/min/
1.73 m2. Furthermore, the eGFR may overestimate true GFR
and the renal function may decline in the near future.
Gliclazide might be a better choice.
If a nephrotoxic drug (renally excreted or not) is considered
to be prescribed, a more conservative approach both in pre-
scribing the drug or choosing the drug dose might be
preferable.
In some clinical situations, a renally excreted drug may be
necessary. Then, the drug dose becomes important, which will
be discussed in the next paragraph.
Therapeutic window
The therapeutic window (TW) reflects the concentration range
that provides efficacy without unacceptable toxicity. In other
words, the area between the minimum efficacious dose and
the maximum tolerable dose [38–40]. The TW may also be
thought of as a range of acceptable plasma levels of the drug
and its active metabolite(s) in which positive therapeutic re-
sults are seen [39]:
Therapeutic window TWð Þ
¼ Minimum toxic plasma concentration
Minimum effective plasma concentration
In order to explain the effect of the TW on reaching toxic
levels, we first illustrate the effect of overestimation and un-
derestimation of the true GFR on the relative steady-state drug
level (rCss) in Table 1. We assumed that an rCss of 100 % is
reached in patients with a normal renal function of 100 ml/
min/1.73 m2 and the recommended drug dose is 100 mg/day.
From our clinical experience, the overestimation of the eGFR,
calculated with the MDRD formula, may become as high as
50–100 % in patients who are completely bedridden for a
prolonged period [41].
Theoretically, when the TWof a drug is 2, with a minimum
relative effective plasma concentration of 70 % and a mini-
mum relative toxic plasma concentration of 140 %, patients
may suffer from a toxic rCss (see Table 1). For example, when
the GFR is overestimated by 25 %, patients suffering from
impaired renal function (<60 ml/min/1.73 m2) will reach an
rCss that exceeds 140 %. If the TW is assumed to be 3 corre-
sponding to a relative therapeutic range of 70–210 %, toxic
levels could also emerge easily. However, if the TWrises to 10
(70–700 %, respectively), it becomes much more difficult to
reach toxic levels (unless the drug level is already near the
minimum toxic level).
In the sequel of the definition of the TW, the question
arises: when is a TW called a narrow therapeutic window
(NTW)?
Recently, Schulz et al. reported for nearly 1000 drugs and
other xenobiotics, therapeutic (“normal”), and, if data were
available, toxic and comatose/fatal blood plasma concentra-
tions [42]. The ranges reported for therapeutic and toxic blood
plasma concentrations could be transformed to the presented
formula earlier.
Definitions for NTW drugs are lacking in the literature. We
suggest that a drug with a TWof 5 or lower can be arbitrarily
defined as a drug with a NTW. Online Resource 2 presents
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examples of renally excreted drugs (or their active metabo-
lites) with a TW of 5 or less. We used the Dutch guidelines
for drug dosing in chronic kidney disease to select drugs
which need dose adjustment, are contraindicated, or need ther-
apeutic drug monitoring in renal impairment [36]. The TW
was calculated with the information summarized by Schulz
et al. [42] and supplemented with recent literature which indi-
cates that toxic levels may be reached easily in patients with
renal impairment [36, 42]. It appeared that for many drugs, we
could not retrieve concrete TW data. Therefore, this list should
be considered as a starting point, which has to be updated
when new information comes available. We recommend a
different approach for drugs with an NTW than for drugs with
a broad therapeutic window (BTW) for drug dosing in patients
with renal impairment [19].
Of note, clinicians should also be aware when a high dose
(near the maximum recommended dose) is needed of a drug
without an NTW, for example, amoxicillin. In the situation of
bacterial meningitis, for example, patients with renal impair-
ment are at increased risk to reach plasma concentration above
the minimum toxic plasma concentration, because the mini-
mum effective dose and therefore the plasma level is higher. A
lower dose should be considered in those situations [43].
Considerations at the start of pharmacotherapy
When a renally cleared drug is needed for a patient with renal
impairment, the starting dose should be considered. The rate at
which the effect of the drugmust be achieved (quickly or not) is
of major importance. The following questions should be asked:
(1) what is the risk of therapeutic failure with lower doses, and
(2) what is the risk of drug toxicity with higher doses [43]?
If the pharmacological effect is needed quickly, one should
consider starting with the recommended dose for patients with
normal renal function. This might be seen as a loading dose
and the dose might be adjusted depending on ADRs and/or
effectiveness. An example is antibiotics. The risk when dosing
too low is insufficient efficacy, but also increasing risk to
develop drug resistance. For most antibiotics, the ADRs are
easy to observe and may be relatively mild. Therefore, starting
with a normal dose is preferable.
In case it is not crucial to have a quick pharmacological
effect, one should preferably use the “start low and go slow
principle”. Examples are statins and antihypertensive drugs.
Especially, for drugs with an NTW, one should consider a
more conservative approach [44].
Considerations during pharmacotherapy
Drug dose recommendations concerning patients with impaired
renal function are usually expressed per renal function category
(50–80, 30–49, 10–29, and <10 ml/min/1.73 m2) [36, 45].
Therefore, recommended dose changes for most drugs are
crude (e.g., halving the dose or changing from twice-a-day
regimen to a once-a-day regimen) [14]. One could argue that
differences between eGFR and the true GFR will remain with-
out practical consequences as long as they do not result in
different renal function categories. However, the factors
Table 1 Theoretical effects of substantial overestimation of eGFR values on relative steady-state drug levels of renally cleared drugs
eGFR
(1.73 ml/min/
m2)
Daily dosea
(mg)
Overestimation
0 % 25 % 50 % 100 %
Corrected
eGFR
Drug levelb
(%)
Corrected
eGFR
Drug levelb
(%)
Corrected
eGFR
Drug levelb
(%)
Corrected
eGFR
Drug levelb
(%)
100 100 100 100 80 125 67 149 50 200
60 100 60 167 48 208 40 250 30 333
40 50 40 125 32 156 27 185 20 250
20 25 20 125 16 156 13 154 10 250
a Recommended dose regimen: 100 mg if eGFR is >50 ml/min/1.73 m2 ; 50 mg if eGFR is 30–50 ml/min/1.73 m2 ; 25 mg if eGFR is 10–30 ml/min/
1.73 m2
b Relative steady-state drug level (rCss) has been calculated as follows: Relative steady state drug level ¼ corresponding drug dose recommendation mg=dayð ÞeGFR corrected for overestimation
This formula is a simplification of the formula [55]
Css ¼ Bioavailabilitydrug doseDosing intervaldrug clearance by making the following assumptions[55]:
-The patient has a normal body surface area of 1.73 m2
-The drug has a bioavailability of 1 (i.e., 100 %)
-The drug has a dosing interval of 1 (i.e., once daily)
-The drug is completely renally cleared
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influencing the variance of the eGFR become more important
as the eGFR approaches the nearest cutoff value for falling into
another renal function category. Then, a minor change in eGFR
over time will lead to different drug dosing recommendations.
It is important to keep in mind that different renal function
categories to guide drug dosing are merely a derivative of a
continuous function that is expressed by the following formula:
fraction of normal dose ¼ 1– f e  1–k Fð Þ
herein, fe is the fraction of the original dose excreted as un-
changed compound (or active metabolite) in the urine, while kF
is the patient’s GFR divided by 120 mL/min [46]. If one indis-
criminately applies drug dose recommendations of 50 % for
eGFRs of 50–30 ml/min and of 25 % for eGFRs of 30–10 ml/
min, a minor change in eGFR from, for example, 31 to 29 ml/
min will halve the drug dose. If it is assumed that the fe for the
particular drug equals 1, the formula earlier will yield a dose of
26 and 24 % for eGFRs of 31 and 29 ml/min, respectively.
Alternatively, one could decide to replace the recommended
doses of half and a quarter of the full drug dose by one third
for eGFRs around 30 ml/min [7]. Following the calculation of
the desired drug dose, the prescribed drug dose must be round-
ed off to the available strengths of the drug in question [47].
Monitoring
Drug efficacy and safety should be monitored after the start of
the therapy. Drug therapy management should be based on
ongoing assessment of clinical status and risk versus benefit
of the current regimen [19]. The Dutch guideline for drug
dosing in patients with renal impairment generally recom-
mends therapeutic drug monitoring (TDM) and/or careful
monitoring of therapeutic effects and/or ADRs for all drugs
with a narrow therapeutic window (see Online Resource 2)
[36].When it is not possible to monitor effectiveness or ADRs
appropriately, or when it is not possible to timely detect seri-
ous ADRs, use of a different drug should be considered.
For a number of drugs monitoring their effectiveness and/
or ADRs (when feasible through TDM) is more important
than dose adjustment according to current guidelines.
Digoxin, for example, is a drug that is difficult to manage,
particularly in elderly patients who are at high risk of de-
creased renal function [48]. High inter-individual variation
for digoxine plasma levels have been observed [49, 50].
Therefore, therapeutic drug monitoring of digoxin is indicat-
ed. Another example is allopurinol. Treat to target serum uric
acid concentrations (<0.36 mmol/l) rather than give a dose
according to renal function has been shown to be safe and
effective [51, 52]. The potential benefits of TDM in patients
with renal impairment has also been observed for ciprofloxa-
cin and amoxicillin/clavulanic acid. In recent studies, the
standard doses frequently resulted in underdosing, especially
in younger patients with good creatinine clearance [53, 54].
One cannot always rely on recommended doses.
Conclusion
DTM based naively on eGFR is not without limitations. In
addition, multimorbidity and drug-drug interactions can fur-
ther complicate clinical decision-making. [42]. The narrower
the therapeutic window of a drug is, the more relevant indi-
vidual patient characteristics are and the less satisfactory crude
dose recommendations become [14].
Therefore, the following considerations in DTM in
patients with renal impairment should be made: (1) Is
the drug renally excreted? If yes, is there a safer alter-
native available?; (2) If not, is it possible that the eGFR
substantially deviates from the true GFR? If yes, con-
sider 24-h urine creatinine clearance collection; (3) Does
the BSA of the patient deviates substantially from
1.73 m2? If yes, calculate BSA and adjust eGFR to
milliliters per minute; (4) Combine consideration 2 and
3 in order to achieve the best approximation of the true
GFR; (5) Adjust the drug dose gradually to the renal
function; (6) Be extra careful with drugs with an NTW and
consider another starting dose depending on indication; (7)
Consider if it is possible to monitor effectiveness and/or
ADRs with TDM and/or other measurements.
In conclusion, when determining most appropriate dosing
regimen for patient with impaired renal function, the serum
creatinine-based formulas should never be used naively but
always in combination with clinical and pharmacological as-
sessment of the individual patient [44].
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